JP2012523243A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523243A5
JP2012523243A5 JP2012505149A JP2012505149A JP2012523243A5 JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5 JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5
Authority
JP
Japan
Prior art keywords
promoter
tumor
stem cell
cytotoxic protein
coding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523243A (ja
JP5727458B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054844 external-priority patent/WO2010119039A1/en
Publication of JP2012523243A publication Critical patent/JP2012523243A/ja
Publication of JP2012523243A5 publication Critical patent/JP2012523243A5/ja
Application granted granted Critical
Publication of JP5727458B2 publication Critical patent/JP5727458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505149A 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 Active JP5727458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16878709P 2009-04-13 2009-04-13
US61/168,787 2009-04-13
PCT/EP2010/054844 WO2010119039A1 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Publications (3)

Publication Number Publication Date
JP2012523243A JP2012523243A (ja) 2012-10-04
JP2012523243A5 true JP2012523243A5 (enExample) 2013-05-23
JP5727458B2 JP5727458B2 (ja) 2015-06-03

Family

ID=42270435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505149A Active JP5727458B2 (ja) 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法

Country Status (12)

Country Link
US (2) US9434925B2 (enExample)
EP (1) EP2419113B1 (enExample)
JP (1) JP5727458B2 (enExample)
KR (1) KR20120088542A (enExample)
CN (1) CN102695517B (enExample)
AU (1) AU2010237130B2 (enExample)
BR (1) BRPI1013771A2 (enExample)
CA (1) CA2758120C (enExample)
IL (1) IL215581A0 (enExample)
RU (1) RU2539099C2 (enExample)
SG (1) SG175127A1 (enExample)
WO (1) WO2010119039A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
KR102053385B1 (ko) * 2012-02-01 2019-12-06 포항공과대학교 산학협력단 12량체 trail 및 hsv-tk 자살유전자를 동시에 발현하는 벡터 및 이를 이용한 항암 줄기세포 치료제
US20130203166A1 (en) * 2012-02-06 2013-08-08 Protobios Llc Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
EP2914102B1 (en) * 2012-11-05 2017-10-18 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2015100268A1 (en) * 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
WO2015108856A2 (en) * 2014-01-17 2015-07-23 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents
EP3182984B1 (en) 2014-08-18 2019-10-30 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
AU2015335607B2 (en) * 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
ES2750008T3 (es) * 2015-02-27 2020-03-24 Apceth Gmbh & Co Kg Células madre mesenquimatosas modificadas genéticamente que expresan klotho
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hiv予備免疫化および免疫療法
KR102201147B1 (ko) 2015-08-11 2021-01-11 카리디 바이오테라퓨틱스, 인크. 암 치료에 사용하기 위한 천연두 백신
WO2017036925A1 (en) * 2015-08-28 2017-03-09 Apceth Gmbh & Co. Kg Mesenchymal stem cells for the treatment of metastatic liver disease
IL279520B2 (en) 2016-01-15 2023-03-01 American Gene Tech Int Inc Methods and preparations for the activation of gamma-delta t cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017214262A1 (en) 2016-06-07 2017-12-14 The Pacific Heart, Lung, & Blood Institute Compositions and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
JP2019535691A (ja) 2016-11-03 2019-12-12 エグゾステム バイオテック リミテッド 間葉系幹細胞集団、それらの生成物およびそれらの使用
WO2018187231A2 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3103423A1 (en) * 2018-06-14 2019-12-19 Loma Linda University Engineered hematopoietic stem cells for the treatment of acute myeloid leukemia
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN113164518B (zh) 2018-10-17 2025-06-24 森迪生物科学公司 组合癌症免疫疗法
WO2020097049A1 (en) * 2018-11-05 2020-05-14 American Gene Technologies International Inc. Vector system for expressing regulatory rna
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
SG10201902002SA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Non-viral modification of mesenchymal stem cells
WO2021038289A1 (en) * 2019-08-23 2021-03-04 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
US20230414730A1 (en) 2020-11-06 2023-12-28 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP3995130A1 (en) 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7098185B2 (en) * 1998-05-18 2006-08-29 University College London Polypeptide hormone phosphatonin
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
US20030165579A1 (en) * 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
JP2006194752A (ja) * 2005-01-14 2006-07-27 Sumitomo Metal Mining Co Ltd X線回折測定における試料固定方法および試料固定具
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
CN103263439B (zh) 2007-05-24 2015-04-22 埃普塞斯有限责任两合公司 Cd34干细胞相关方法和组合物

Similar Documents

Publication Publication Date Title
JP2012523243A5 (enExample)
RU2011146048A (ru) Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
JP2010528008A5 (enExample)
Pol et al. Trial watch: oncolytic viruses for cancer therapy
Power et al. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer
Rahal et al. Oncolytic viral therapy for pancreatic cancer
JP2008056679A5 (enExample)
JP2024045608A (ja) 制御性rnaを発現させるためのベクターシステム
JP2012010710A5 (enExample)
CA2640528A1 (en) Oncolytic adenoviruses for cancer treatment
Shi et al. Engineered mesenchymal stem/stromal cells against cancer
Feng et al. Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog
JP2016526920A5 (enExample)
Cao et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter
Patil et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
Bilsland et al. Virotherapy: cancer gene therapy at last?
Lucas et al. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer
Svyatchenko et al. Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines
Shen et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene
Hemminki From molecular changes to customised therapy
Tang et al. Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer
Gürlevik et al. Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication
Singh Role of gene therapy in treatment of cancer for craniofacial regeneration—current molecular strategies, future perspectives, and challenges: a narrative review
WO2006125381A1 (en) Tumor targeting gene-virus zd55-il-24, construction method and application thereof
RU2814581C1 (ru) Генетический вектор Ad6/3-hTERT-GMCSF, содержащий геномные последовательности рекомбинантного аденовируса 6 серотипа, промотор теломеразы человека, ген гранулоцитарно-макрофагального колониестимулирующего фактора человека, а также ген белка файбер со встройкой домена fiber knob аденовируса 3 серотипа, обладающий повышенной трансдукцией в опухолевые клетки